Vyome Holdings, Inc. Q4 FY2023 earnings call

• ReShape remains dedicated to achieving profitability through cost reductions and focusing on growth pillars. They aim to reduce core operating expenses by $24 million or 75% from 2022 to 2024.
• The limited launch of the Lap-Band 2.0 FLEX is progressing with positive surgeon feedback. Their revamped patient-friendly website is receiving meaningful traffic, and co-op marketing programs with key Lap-Band centers are effective.
• They have a partnership with Hive Medical for cost-effective digital lead generation and patient engagement, using AI SMS patient self-service technology to enhance patient experience.
• They are searching for strategic M&A opportunities to expand their portfolio or distribution and continue development of new products and therapies.

For the year ended December 31, 2023, ReShape Lifesciences' revenue totaled $8.7 million, a contraction of $2.6 million compared to the same period in 2022. The primary reason for this decrease is the introduction of GLP-1 prescriptions within the U.S., leading to a 27% decrease in Lap-Band unit sales. Revenue contribution is primarily from the Lap-Band product line.

• Anticipate revenues increasing in 2024 with the full U.S. launch of the Lap-Band 2.0 FLEX.
• Expect continued reduction in operating expenses in 2024, with core operating expense reductions between 2022 and 2024 estimated at $24 million or 75%.

• Impact of GLP-1 agonist prescription drugs on the bariatric surgery market, including limitations in weight loss duration, cost, and accessibility.
• Uncertainties in the high-priority search for strategic M&A opportunities.

Q: No specific questions detailed in the provided transcript A: No specific answers provided in the transcript